PALB2 and pancreatic adenocarcinoma: A Randomised Phase II Study of Gemcitabine, Cisplatin +/−Veliparib in Patients With Pancreas Adenocarcinoma and a Known BRCA/PALB2 Mutation (Part I) and a Phase II Single Arm Study of Single-Agent Veliparib in Previously Treated Pancreas Adenocarcinoma